Aveo Pharmaceuticals: Jefferies Global Healthcare Conference (Aveo Oncology) - Jun 7, 2014 - "Phase 1 AV-203 Dose-Escalation, Monotherapy Study Completed"; "22 subjects enrolled: Tumor types: 4 NSCLC (3 sq. 1 adeno); 4 CRC; 2 sq cell skin; one each ovarian, peritoneal, SCLC, endometroid, osteosarcoma, HCC, pancreatic nuroendocrine, bladder, mesothelioma, SCCHN, cervical"; "Most common treatment-related AEs were diarrhea (59%), dry skin and decreased appetite (32% each): 1 DLT observed"; "Encouraging early efficacy and support for NRG-1/HRG biomarker hypothesis: Of 22 patients, 8 SD and 1 PR, 1 of 2 NRG-1/HRG positive patients experienced a PR" "
P1 data • Oncology
|